Αποτελέσματα Αναζήτησης
15 Οκτ 2010 · In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced non-small-cell lung cancer (NSCLC).
29 Ιαν 2024 · Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): Primary endpoint results of a phase II clinical trial. Matthew Rettig , John Shen , Robert Evan Reiter , Alan Lee , Michael L. Steinberg , Luca Faustino Valle , Ankush Sachdeva , Tahmineh Romero , Jeremie Calais , Johannes Czernin , Nicholas George ...
20 Δεκ 2010 · Recently, Cappuzzo et al Citation 50 presented data from the Sequential Tarceva in Unresectable NSCLC (SATURN) trial a double-blind, randomized, phase III study of maintenance erlotinib vs placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. The final results of the study found that the ...
The first study compared Tarceva with chemotherapy in 173 patients with advanced NSCLC with activating EGFR mutations who had not received previous chemotherapy. Patients taking Tarceva lived for an average of 10.4 months without their disease getting worse compared with 5.1 months for those receiving chemotherapy medicines.
20 Μαΐ 2010 · We designed the phase 3, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study to investigate the effect of erlotinib as maintenance therapy on PFS in patients with non-progressive disease following first-line platinum-doublet chemotherapy.
The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy. It demonstrated a significant improvement in overall survival from 11.1 months in the placebo group to 12.3 months in patients receiving maintenance erlotinib, with the important caveat ...
1 Δεκ 2010 · The Sequential Tarceva in Unresectable NSCLC (SATURN) study investigated the use of maintenance erlotinib following the completion of first-line chemotherapy.
